✦ LIBER ✦
7008 POSTER DISCUSSION Twenty-four-month Safety Data From Phase II Studies of Radium-223 Chloride, a First-in-class Alpha-pharmaceutical With a Highly Favorable Safety Profile for Patients With Castration-resistant Prostate Cancer (CRPC) and Bone Metastases
✍ Scribed by Nilsson, S.; Haugen, I.; Aksnes, A.; O'Bryan-Tear, C.G.; Parker, C.
- Book ID
- 123150882
- Publisher
- Elsevier Science
- Year
- 2011
- Tongue
- English
- Weight
- 43 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0959-8049
No coin nor oath required. For personal study only.